Using the MEK inhibitor U0126 and the PI3K inhibitor LY294002 to treat lung cancer cells, we found that the MAPK/ERK and PI3K/AKT pathways are involved in the regulation of IL6 expression. This evidence concerns the gene AKT1 and lung carcinoma.